\-\ Texto\\:\\ \ \(0\)\
\-\ gastrin\\ 1416\\ \\(nl\\ 0\\-42\\)\ \(0\)\
\-\ the\\ patient\\ is\\ scheduled\\ for\\ surgery\\.\ \(1\)\
\-\ on\\ ct\\,\\ gastrinomas\\ are\\ hypervascular\\ and\\ average\\ 3\\-4\\ cm\\ in\\ diameter\\.\\ \\ in\\ over\\ one\\-half\\ of\\ cases\\,\\ multiple\\ lesions\\ are\\ present\\.\\ \\ thickened\\ gastric\\ and\\ small\\ bowel\\ folds\\ may\\ be\\ present\\ from\\ increased\\ gastric\\ acid\\ secretion\\ and\\ malabsorption\\.\\ \\ approximately\\ 60\\%\\ of\\ patients\\ have\\ metastases\\ at\\ the\\ time\\ of\\ diagnosis\\,\\ most\\ often\\ to\\ the\\ liver\\ and\\ lymph\\ nodes\\.\ \(0\)\
\-\ islet\\ cell\\ tumors\\ typically\\ express\\ somatostatin\\ receptors\\,\\ making\\ them\\ amenable\\ to\\ octreoscan\\ imaging\\ where\\ they\\ demonstrate\\ abnormally\\ increased\\ uptake\\ of\\ the\\ radiotracer\\.\ \(0\)\
\-\ gastrinoma\ \(10\)\
\-\ ductal\\ adenocarcinoma\ \(2\)\
\-\ islet\\-cell\\ tumor\\:\\ insulinoma\\,\\ gastrinoma\\,\\ nonfunctioning\\,\\ glucagonoma\\,\\ somatostatinoma\\,\\ vipoma\ \(0\)\
\-\ lymphoma\ \(373\)\
\-\ metastases\\:\\ melanoma\\,\\ renal\\ cell\\,\\ breast\\,\\ lung\\,\\ stomach\ \(0\)\
\-\ solid\\ and\\ papillary\\ epithelial\\ neoplasm\ \(0\)\
\-\ mimics\\:\\ peripancreatic\\ adenopathy\\,\\ adrenal\\ mass\\,\\ splenule\ \(0\)\
\-\ focal\\ pancreatitis\ \(1\)\
\-\ idiopathic\\ fibrosing\\ pancreatitis\ \(0\)\
\-\ pancreaticoblastoma\\:\\ children\ \(0\)\
\-\ acinar\\ cell\\ carcinma\ \(0\)\
\-\ 85\\ yo\\ male\\ w\\/\\ h\\/o\\ distant\\ rcc\\ s\\/p\\ rt\\ nephrectomy\\ now\\ w\\/\\ transaminitis\\.\ \(0\)\
\-\ this\\ was\\ a\\ rather\\ unusual\\ presentation\\ for\\ a\\ gastrinoma\\ in\\ that\\ there\\ were\\ no\\ mets\\ identified\\ by\\ imaging\\,\\ and\\ the\\ patient\\ had\\ no\\ complaints\\ of\\ elevated\\ gastrin\\ levels\\.\\ \\ unfortunately\\,\\ the\\ patient\\ had\\ poor\\ kidney\\ function\\ and\\ could\\ not\\ receive\\ iv\\ contrast\\,\\ limiting\\ the\\ ct\\ imaging\\.\\ \\ however\\,\\ with\\ the\\ positive\\ octreoscan\\ and\\ dramatically\\ increased\\ serum\\ gastrin\\ level\\,\\ the\\ pancreatic\\ head\\ mass\\ is\\ consistent\\ with\\ a\\ gastrinoma\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ gastrinoma\\:\\ 0\\.38606996947086664\ \(0\)\
\-\ gastrin\\:\\ 0\\.3019323223261384\ \(0\)\
\-\ octreoscan\\:\\ 0\\.2138181088245518\ \(0\)\
\-\ islet\\:\\ 0\\.1743406718904329\ \(0\)\
\-\ cell\\:\\ 0\\.16008216307342304\ \(0\)\
\-\ pancreatitis\\:\\ 0\\.13875361185613658\ \(0\)\
\-\ the\\:\\ 0\\.12563661493266928\ \(0\)\
\-\ gastric\\:\\ 0\\.11786122829596825\ \(0\)\
\-\ and\\:\\ 0\\.1156515907128403\ \(0\)\
\-\ increased\\:\\ 0\\.11349368423268943\ \(0\)\
\-\ metastases\\:\\ 0\\.11311807734104469\ \(0\)\
\-\ 1416\\:\\ 0\\.11188182257893269\ \(0\)\
\-\ glucagonoma\\:\\ 0\\.11188182257893269\ \(0\)\
\-\ somatostatinoma\\:\\ 0\\.11188182257893269\ \(0\)\
\-\ splenule\\:\\ 0\\.11188182257893269\ \(0\)\
\-\ pancreaticoblastoma\\:\\ 0\\.11188182257893269\ \(0\)\
\-\ carcinma\\:\\ 0\\.11188182257893269\ \(0\)\
\-\ imaging\\:\\ 0\\.1102995872550263\ \(0\)\
\-\ gastrinomas\\:\\ 0\\.1069090544122759\ \(0\)\
\-\ vipoma\\:\\ 0\\.1069090544122759\ \(0\)\
\-\ acinar\\:\\ 0\\.1033808192487598\ \(0\)\
\-\ transaminitis\\:\\ 0\\.1033808192487598\ \(0\)\
\-\ express\\:\\ 0\\.10064410744204613\ \(0\)\
\-\ somatostatin\\:\\ 0\\.10064410744204613\ \(0\)\
\-\ receptors\\:\\ 0\\.10064410744204613\ \(0\)\
\-\ mimics\\:\\ 0\\.10064410744204613\ \(0\)\
\-\ insulinoma\\:\\ 0\\.098408051082103\ \(0\)\
\-\ nonfunctioning\\:\\ 0\\.09487981591858693\ \(0\)\
\-\ amenable\\:\\ 0\\.0934352829154462\ \(0\)\
\-\ dramatically\\:\\ 0\\.0934352829154462\ \(0\)\
\-\ peripancreatic\\:\\ 0\\.09097418619856455\ \(0\)\
\-\ malabsorption\\:\\ 0\\.08990704775193012\ \(0\)\
\-\ fibrosing\\:\\ 0\\.08990704775193012\ \(0\)\
\-\ secretion\\:\\ 0\\.08892537554208416\ \(0\)\
\-\ rcc\\:\\ 0\\.08247318286839167\ \(0\)\
\-\ limiting\\:\\ 0\\.0809053889749867\ \(0\)\
\-\ rt\\:\\ 0\\.07866933261504357\ \(0\)\
\-\ nl\\:\\ 0\\.07677877390065721\ \(0\)\
\-\ them\\:\\ 0\\.07609724549951355\ \(0\)\
\-\ folds\\:\\ 0\\.07545160404525446\ \(0\)\
\-\ epithelial\\:\\ 0\\.07514109745152749\ \(0\)\
\-\ hypervascular\\:\\ 0\\.07397217953821879\ \(0\)\
\-\ receive\\:\\ 0\\.07369656444838675\ \(0\)\
\-\ distant\\:\\ 0\\.07316324758325281\ \(0\)\
\-\ average\\:\\ 0\\.07290504109158435\ \(0\)\
\-\ acid\\:\\ 0\\.07265215882632774\ \(0\)\
\-\ unfortunately\\:\\ 0\\.07216151918684885\ \(0\)\
\-\ mets\\:\\ 0\\.07192336888173839\ \(0\)\
\-\ present\\:\\ 0\\.07179785086258732\ \(0\)\
\-\ nephrectomy\\:\\ 0\\.07146050808844363\ \(0\)\
\-\ making\\:\\ 0\\.06996560805210283\ \(0\)\
\-\ had\\:\\ 0\\.06971363257994584\ \(0\)\
\-\ abnormally\\:\\ 0\\.06956994937405728\ \(0\)\
\-\ of\\:\\ 0\\.0684546495999387\ \(0\)\
\-\ patient\\:\\ 0\\.06826376473180966\ \(0\)\
\-\ melanoma\\:\\ 0\\.06533259444714837\ \(0\)\
\-\ papillary\\:\\ 0\\.06519556111821388\ \(0\)\
\-\ scheduled\\:\\ 0\\.0649260039960758\ \(0\)\
\-\ adrenal\\:\\ 0\\.06479341507934686\ \(0\)\
\-\ 85\\:\\ 0\\.0645324615039292\ \(0\)\
\-\ pancreatic\\:\\ 0\\.06342236555156551\ \(0\)\
\-\ unusual\\:\\ 0\\.06273446440133222\ \(0\)\
\-\ serum\\:\\ 0\\.06273446440133222\ \(0\)\
\-\ rather\\:\\ 0\\.06197783254842478\ \(0\)\
\-\ ductal\\:\\ 0\\.06156554648802352\ \(0\)\
\-\ radiotracer\\:\\ 0\\.0610689460438844\ \(0\)\
\-\ nodes\\:\\ 0\\.05943126959475468\ \(0\)\
\-\ idiopathic\\:\\ 0\\.05917838732949804\ \(0\)\
\-\ thickened\\:\\ 0\\.05901265027557751\ \(0\)\
\-\ poor\\:\\ 0\\.05901265027557751\ \(0\)\
\-\ adenopathy\\:\\ 0\\.05884912311496392\ \(0\)\
\-\ stomach\\:\\ 0\\.058371230630429656\ \(0\)\
\-\ complaints\\:\\ 0\\.05761393112977186\ \(0\)\
\-\ children\\:\\ 0\\.05732363697732927\ \(0\)\
\-\ adenocarcinoma\\:\\ 0\\.05718102658736847\ \(0\)\
\-\ function\\:\\ 0\\.05662661104722786\ \(0\)\
\-\ diameter\\:\\ 0\\.05622665097313751\ \(0\)\
\-\ levels\\:\\ 0\\.05546385457858379\ \(0\)\
\-\ where\\:\\ 0\\.05498046766276219\ \(0\)\
\-\ lymph\\:\\ 0\\.054401853034787624\ \(0\)\
\-\ uptake\\:\\ 0\\.0537954018138132\ \(0\)\
\-\ solid\\:\\ 0\\.05363508116034594\ \(0\)\
\-\ mass\\:\\ 0\\.05344596861016012\ \(0\)\
\-\ ct\\:\\ 0\\.05326912061486299\ \(0\)\
\-\ are\\:\\ 0\\.05309353854305215\ \(0\)\
\-\ 60\\:\\ 0\\.05232698495629465\ \(0\)\
\-\ in\\:\\ 0\\.05221159024399731\ \(0\)\
\-\ tumors\\:\\ 0\\.0514522324992461\ \(0\)\
\-\ could\\:\\ 0\\.05088775545825148\ \(0\)\
\-\ breast\\:\\ 0\\.05080317336199235\ \(0\)\
\-\ they\\:\\ 0\\.04998796601582708\ \(0\)\
\-\ iv\\:\\ 0\\.04998796601582708\ \(0\)\
\-\ identified\\:\\ 0\\.049599821110629196\ \(0\)\
\-\ kidney\\:\\ 0\\.04914970250585418\ \(0\)\
\-\ typically\\:\\ 0\\.04911292779959898\ \(0\)\
\-\ liver\\:\\ 0\\.048261879734008896\ \(0\)\
\-\ presentation\\:\\ 0\\.04815953403287172\ \(0\)\
\-\ now\\:\\ 0\\.04802438825382122\ \(0\)\
\-\ neoplasm\\:\\ 0\\.047758483955342906\ \(0\)\
\-\ elevated\\:\\ 0\\.047692899011097564\ \(0\)\
\-\ cases\\:\\ 0\\.04705564630911289\ \(0\)\
\-\ positive\\:\\ 0\\.04610027451071391\ \(0\)\
\-\ often\\:\\ 0\\.04564912091740712\ \(0\)\
\-\ no\\:\\ 0\\.04550061647707465\ \(0\)\
\-\ bowel\\:\\ 0\\.04489745913359997\ \(0\)\
\-\ approximately\\:\\ 0\\.044639795132492124\ \(0\)\
\-\ yo\\:\\ 0\\.043707255090538785\ \(0\)\
\-\ renal\\:\\ 0\\.043566283936768084\ \(0\)\
\-\ lung\\:\\ 0\\.04255768667692664\ \(0\)\
\-\ for\\:\\ 0\\.042408887486752\ \(0\)\
\-\ level\\:\\ 0\\.04226009673036202\ \(0\)\
\-\ focal\\:\\ 0\\.04184711645461815\ \(0\)\
\-\ head\\:\\ 0\\.04172588625487051\ \(0\)\
\-\ lymphoma\\:\\ 0\\.04166571758792434\ \(0\)\
\-\ time\\:\\ 0\\.041467260905759445\ \(0\)\
\-\ however\\:\\ 0\\.04140834475396256\ \(0\)\
\-\ cm\\:\\ 0\\.040179019927022705\ \(0\)\
\-\ lesions\\:\\ 0\\.040179019927022705\ \(0\)\
\-\ patients\\:\\ 0\\.03935652037210834\ \(0\)\
\-\ over\\:\\ 0\\.03890102777089284\ \(0\)\
\-\ is\\:\\ 0\\.038318231754175675\ \(0\)\
\-\ consistent\\:\\ 0\\.03793410523852761\ \(0\)\
\-\ surgery\\:\\ 0\\.03761364066706712\ \(0\)\
\-\ tumor\\:\\ 0\\.036593319666658936\ \(0\)\
\-\ most\\:\\ 0\\.03640948220438301\ \(0\)\
\-\ demonstrate\\:\\ 0\\.03637044443557068\ \(0\)\
\-\ diagnosis\\:\\ 0\\.036266947151770965\ \(0\)\
\-\ small\\:\\ 0\\.03608790228803006\ \(0\)\
\-\ were\\:\\ 0\\.03606253649750488\ \(0\)\
\-\ may\\:\\ 0\\.0352062517603659\ \(0\)\
\-\ to\\:\\ 0\\.034979897813925825\ \(0\)\
\-\ have\\:\\ 0\\.03494902992249325\ \(0\)\
\-\ multiple\\:\\ 0\\.03421912751426788\ \(0\)\
\-\ contrast\\:\\ 0\\.03399230338082311\ \(0\)\
\-\ male\\:\\ 0\\.031149036991192047\ \(0\)\
\-\ that\\:\\ 0\\.030360166247214312\ \(0\)\
\-\ by\\:\\ 0\\.029709220140905827\ \(0\)\
\-\ be\\:\\ 0\\.028380115234166305\ \(0\)\
\-\ there\\:\\ 0\\.027837004283138855\ \(0\)\
\-\ from\\:\\ 0\\.027785283150725534\ \(0\)\
\-\ not\\:\\ 0\\.027618680150420096\ \(0\)\
\-\ with\\:\\ 0\\.02739822049470513\ \(0\)\
\-\ at\\:\\ 0\\.026424908102257075\ \(0\)\
\-\ was\\:\\ 0\\.02438187298407367\ \(0\)\
\-\ this\\:\\ 0\\.024039634534748416\ \(0\)\
\-\ on\\:\\ 0\\.02112922513687097\ \(0\)\
